SOLID BIOSCIENCES—$SLDB CASHES UP FOR GENE THERAPY PUSH

SOLID BIOSCIENCES—SLDB CASHES UP FOR GENE THERAPY PUSH
(1/9)
Good afternoon, Tradingview! Solid Biosciences is stacking cash—no revenue yet, but a $200M raise has tongues wagging 📈🔥. SLDB’s betting big on gene therapy—here’s the scoop! 🚀

(2/9) – CASH, NOT SALES

• Revenue: Zilch—clinical-stage vibes 💥
• Q3 ‘24 Loss: $0.61/share, missed $0.58 est. 📊
• Cash Boost: $200M offering just landed
No sales, but SLDB’s war chest is growing!

(3/9) – BIG MOVE

• Feb 18 Raise: $200M via 35.7M shares, warrants 🌍
• Cash Pile: Was $171M, now nearing $350M 🚗
• Goal: Fuel SGT-003 trials into ‘27 🌟
SLDB’s loading up for the long haul!

(4/9) – SECTOR CHECK

• Market Cap: $500M post-raise 📈
• Vs. Peers: Sarepta’s 13B dwarfs it—revenue rules
• Edge: Low EV ($150M), big therapy dreams
Undervalued biotech bet or long shot? 🌍

(5/9) – RISKS ON DECK

• Trials: SGT-003 flops could sink it ⚠️
• Sentiment: 30% drop from Jan peak—jitters 🏛️
• Burn: $20-25M/quarter—clock’s ticking 📉
High stakes, high risks—can it deliver?

(6/9) – SWOT: STRENGTHS

• Cash: $200M raise powers trials 🌟
• SGT-003: Early data dazzles, Fast Track nod 🔍
• DMD Focus: Huge need, blockbuster shot 🚦
SLDB’s got fuel and firepower!

(7/9) – SWOT: WEAKNESSES & OPPORTUNITIES

• Weaknesses: No revenue, all-in on one play 💸
• Opportunities: $2-4B cap if trials pop 🌍
Can SLDB turn cash into a cure?

(8/9) – SLDB’s $200M haul—your take?

1️⃣ Bullish—Gene therapy gold ahead.
2️⃣ Neutral—Wait for trial proof.
3️⃣ Bearish—Risks outweigh the buzz.

Vote below! 🗳️👇

(9/9) – FINAL TAKEAWAY

SLDB’s revenue-free, but $200M keeps SGT-003 alive—stock’s buzzing 🌍🪙. Low EV vs. peers, yet trials and rivals loom. Cure or bust?